SciBase announces outcome of rights issue of shares

SciBase announced that its approximately SEK 57.5 million rights issue received subscriptions for 2,681,085 shares worth approximately SEK 40.2 million through subscription rights. This represents a 69.9% subscription rate as of the close of the subscription period on 29 September 2026, leaving part of the offering not covered by rights-based subscriptions.

Analysis

The key signal is not the gross proceeds but the degree to which existing holders funded the raise: strong rights take-up reduces immediate underwriting/placement overhang and suggests the shareholder base remains willing to finance the commercialization runway. However, a sub-fully subscribed transaction still leaves SCIB exposed to recurring-equity-financing perceptions unless management can demonstrate that this capital bridges to a defined operating inflection rather than another raise within 12-18 months.

Near term, the stock can trade better than a typical discounted issuance if short sellers had positioned for a failed deal and the residual allocation is absorbed cleanly. The 1-3 month catalyst is the final dilution math, including any subscription commitments or guarantee allocations, and management’s updated cash-runway guidance; investors should focus on quarterly cash burn, US commercial traction, and gross-margin progression rather than the headline funding amount.

The contrarian point is that this is potentially a liquidity de-risking event, not automatically a fundamental re-rating. For a small medtech issuer, financing removes insolvency-tail risk but can cap upside if sales execution remains below the fixed-cost base. A durable 6-18 month rerating requires evidence that Nevisense adoption converts into recurring consumables or reimbursed procedure volume; absent that, the equity remains primarily a financing-cycle trade.

Key Decisions for Investors

• Maintain a neutral-to-watch stance on SCIB immediately after settlement; do not chase a post-financing relief rally without confirmation of final new-share count, issue price, and pro-forma cash runway.
• Consider a small tactical long only if SCIB holds above the rights-adjusted issue price for 10-15 trading days and management guides to at least 12 months of runway; target a 15-25% relief-rally return over 1-3 months, with a stop on a break below the issue-price support level.
• For existing holders, treat the next two earnings reports as the validation window: reduce exposure if operating cash burn does not fall sequentially or if commercial/reimbursement KPIs fail to accelerate, as another equity raise would likely drive material multiple compression.
• Set an event alert for any revised 2027 financing requirement, distributor expansion, US reimbursement decision, or material order announcement. A verified reimbursement or recurring-revenue catalyst would be more consequential than the completed raise and could justify reassessing SCIB as a 6-18 month long.